Healthhope

Kangchen Pharmaceutical, also known as Healthhope, is a leading Chinese biopharmaceutical company specializing in the development and commercialization of innovative therapies for oncology and surgical care. The company's flagship product, Suling (Hemocoagulase Agkistrodon for Injection), is a proprietary, single-component hemostatic agent derived from snake venom that holds a dominant position in the Chinese surgical market. Kangchen's research and development strategy focuses on targeted small molecule inhibitors, with its lead candidate KC1036 currently in Phase 2 clinical trials for various solid tumors, including esophageal and lung cancers. Publicly listed on the Shanghai Stock Exchange, the company maintains a strong commitment to addressing unmet medical needs through its proprietary drug discovery platforms. With a robust commercial infrastructure and a growing pipeline of targeted therapies, Kangchen is a key player in the evolving Chinese biotechnology landscape.